Novelty:
This invention is a novel means of augmenting immune-based cancer therapies by using a physical intervention to counter a tumor's natural immunosuppressive effect.
Value Proposition:
This therapeutic strategy combines two accepted approaches to cancer management - immune-based and physical - for an increase in survival that is durable and significantly greater than additive. The antigen-agnostic effect and immune priming beyond a tumor's margins points to a novel means of treatment that can be broadly applied to all solid cancers. Other advantages include:
• Proof of concept in vivo studies demonstrated.
• Safety of combination demonstrated in mouse model.
• Potential to be combined with a range of immunotherapy’s including monoclonal antibodies.
• Applications across a wide variety of solid cancers.
Technical Details:
Johns Hopkins researchers have developed a novel cancer treatment method that combines physical intervention with current immune-based cancer therapies. The physical intervention acts as a primer that both offsets the suppressive effects of tumors and activates the immune system and augments treatments. This combination method demonstrates improved survival rates over either therapy alone.
Looking for Partners:
To develop and commercialize the technology as a novel treatment approach to augment the effect of various immunotherapies for a variety of solid cancers.
Stage of Development:
Pre-Clinical
Data Availability:
Under CDA / NDA
Publications/Associated Cases:
Not available at this time
